Roivant Sciences Ltd.
ROIV
Ранг среди акций
#980
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Цена акции
$33.73
Последняя синхронизация: 2026-07-31
Рыночная капитализация
$24.37B
Изменение (1 день)
-2.28%
Изменение (1 год)
95.44%
Страна
GB
Торговля Roivant Sciences Ltd. (ROIV)
Категория
Healthcare
EPS для Roivant Sciences Ltd. (ROIV)
EPS по состоянию на June 2026 TTM: $-0.38
Согласно последним финансовым отчетам и цене акций Roivant Sciences Ltd., текущий EPS компании (TTM) составляет $-0.38. В конце 2024 EPS компании составлял $5.55, больше, чем показателю 2023 года, равному $-1.42.
История EPS компании Roivant Sciences Ltd. с 2020 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-0.38 | 58.33% |
| 2025 | $-0.24 | -104.32% |
| 2024 | $5.55 | -490.85% |
| 2023 | $-1.42 | 12.70% |
| 2022 | $-1.26 | 6.78% |
| 2021 | $-1.18 | -167.43% |
| 2020 | $1.75 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -4,657.89% |
US
|
|
| $-7.98 | 2,000.00% |
US
|
|
| $-5.29 | 1,292.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,400.00% |
NL
|
